[ad_1]
jetcityimage/iStock Editorial through Getty Photos
Walgreens Boots (NASDAQ:WBA) is scheduled to announce Q2 earnings outcomes on Tuesday, March twenty eighth, earlier than the market opens.
The consensus EPS Estimate is $1.11 (-30.2% Y/Y) and the consensus Income Estimate is $33.56B (-0.6% Y/Y).
Over the past 2 years, WBA has overwhelmed EPS estimates 100% of the time and has overwhelmed income estimates 88% of the time.
Over the past 3 months, EPS estimates have seen 1 upward revision and 12 downward. Income estimates have seen 9 upward revisions and 0 downward.
The corporate on Jan. 5 reported Q1 Non-GAAP EPS of $1.16, beating estimates by 2 cents. Income of $33.38B was forward of consensus by $340M.
WBA has a Quant ranking of HOLD, with a 3.22 ranking rating.
WBA has an business rating of 74 out of 191 within the client staples sector, however is the highest rating inventory within the drug retail business, as per SA’s Quant rating.
Wall Avenue analysts charge the WBA inventory HOLD, whereas Looking for Alpha authors charge it BUY.
Current Evaluation: “The place WBA’s inventory heads within the subsequent a number of years will largely rely upon how properly its Healthcare phase performs. Whereas I like the concept of increasing into totally different areas of care to assist drive down prices, I believe proudly owning medical practices and pharmacies can get a bit messy. I see the logic in it, however I additionally see the chances of abuse as properly,” Looking for Alpha contributor Geoffrey Seiler wrote in a lately revealed evaluation.
“Walgreens Boots Alliance’s inventory has skilled a big decline since reaching its peak of $87 in 2015, presently at $33. The principle issue driving this decline is the drop in margins from 29% in August 2013 to twenty% at this time, attributed to larger prices, decrease reimbursements, and elevated competitors. Regardless of this, I imagine that the market has been too harsh on WBA. Though reimbursement pressures are anticipated to persist, I believe that WBA’s shift in technique and the current acquisition will present some mild on the finish of the tunnel. Based mostly on my evaluation, I worth the shares at $40, representing a 21% upside along with the +5% dividend,” SA contributor George Atuan mentioned.
Current Information: Earlier this month, California Governor Newsom canceled a $54M contract with WBA over the corporate’s choice to not promote abortion capsules (Mifepristone) in sure states.
WBA inventory fell 25% in 2022, whereas the benchmark S&P 500 index slipped practically 20% for the 12 months.
[ad_2]
Source link
